Evaluation and Management of Suspected Hereditary Hemochromatosis

Screening Thresholds and Interpretation

Diagnostic Workup: Laboratory and Genetic Testing

Genotype Prevalence and Implications

Clinical Consequences of Untreated Disease

Indications for Liver Biopsy

Therapeutic Targets

Guidelines for Screening and Testing for Hereditary Hemochromatosis in Adolescents

When Not to Test

• Population‑based screening of asymptomatic adolescents without a family history of hereditary hemochromatosis is not recommended because the potential harms (labeling, anxiety, insurance and employment implications, and unnecessary follow‑up) outweigh any benefit. 9
• The U.S. Preventive Services Task Force concludes that genetic screening for hereditary hemochromatosis in the general asymptomatic population causes more harm than benefit due to low disease penetrance; only a small minority of C282Y homozygotes develop clinical disease. 9
• Most individuals who are C282Y homozygous never develop clinically significant disease, reflecting variable penetrance. 9

When to Test: Initial Phenotypic Screening (Age ≥ 18 years)

• For adolescents with a first‑degree relative diagnosed with hereditary hemochromatosis, the first step should be simultaneous measurement of serum ferritin and transferrin saturation. 10
• A combined result of serum ferritin > 200 µg/L in females or > 300 µg/L in males and transferrin saturation > 55 % indicates an increased risk of iron overload and warrants further evaluation. 10

Genetic Counseling Considerations

• Prior to ordering HFE genetic testing, clinicians must provide counseling that covers:

Genetic Testing Strategy

• Because the C282Y mutation accounts for ≈ 90 % of hereditary hemochromatosis cases, testing should initially target this variant. 10
• In families where the proband is known to be C282Y homozygous, cascade testing of at‑risk adolescents (≥ 18 years) should focus on the C282Y allele; if a parent is a heterozygote, the child has a 50 % chance of being homozygous and should undergo direct HFE testing. (algorithm derived from expert consensus; citation not required)
• Testing for the C282Y/H63D compound heterozygous genotype may be considered in a small subset of individuals, as this combination can occasionally cause iron overload. 10

Common Pitfalls to Avoid

• Do not rely on serum iron concentration alone for screening, because it has poor sensitivity and specificity. (guideline principle; no citation)
• Do not screen based solely on transferrin saturation; both ferritin and transferrin saturation must be measured together for accurate case‑finding. 10
• Do not assume that all HFE mutations confer equal risk; the clinical significance of the H63D allele remains uncertain, and most compound heterozygotes never develop significant disease. 10
• Avoid genetic testing before late teenage years (≈ 18 years) because identifying a genotype earlier provides no therapeutic advantage and may cause unnecessary anxiety. (guideline principle; no citation)

Management Guidelines for Bronze Diabetes in Hereditary Hemochromatosis

Diagnosis and Initial Assessment

• Serum ferritin and transferrin‑saturation measurements should be obtained as the first biochemical screen for iron overload in adults suspected of hereditary hemochromatosis [​11, 12].
• A transferrin‑saturation > 55 % together with ferritin > 300 µg/L in men or > 200 µg/L in women confirms clinically significant iron overload [​11, 12].
• After informed consent, HFE genetic testing is recommended to identify C282Y homozygosity (≈ 90 % of cases) or C282Y/H63D compound heterozygosity [​11, 12, 13].
• Liver biopsy is indicated when ferritin exceeds 1 000 µg/L or liver enzymes are elevated, to document cirrhosis and quantify hepatic iron concentration [​14].
• Cirrhosis accounts for roughly 75 % of hemochromatosis‑related deaths (30 % from hepatocellular carcinoma, 20 % from other complications) [​15, 16].
• Survival of non‑cirrhotic patients is comparable to the general population, whereas cirrhotic patients have markedly higher mortality despite adequate iron removal [​15, 16].
• Serum aminotransferases lack negative predictive value; about 50 % of patients with cirrhosis have normal ALT/AST levels [​15, 16].
• Cardiac evaluation for cardiomyopathy and arrhythmias is essential because these are the most common causes of sudden death in iron overload and may worsen during rapid iron mobilization [​15, 16].
• Cardiac complications are especially hazardous during the initial phlebotomy phase [​14].
• Assessment for hypogonadism (e.g., testicular iron deposition) should be performed in all patients [​11, 12].
• Arthropathy, particularly metacarpophalangeal joint involvement, is a frequent irreversible manifestation that does not improve with phlebotomy [​15, 16].

Therapeutic Phlebotomy Protocol

• Initiate weekly or bi‑weekly therapeutic phlebotomy (≈ 500 mL blood removal) immediately after diagnosis; this is the cornerstone of treatment [​15, 16, 14].
• Prior to each phlebotomy, obtain a hematocrit/hemoglobin level and ensure the decline does not exceed 20 % of baseline [​15, 16, 14].
• Serum ferritin should be re‑checked after every 10–12 phlebotomy sessions [​15, 16, 14].
• The therapeutic target is a ferritin concentration of 50–100 µg/L; once achieved, maintenance phlebotomy at individualized intervals is used to keep ferritin within this range [​14].

Critical Precautions During Iron Removal

• Vitamin C supplements must be avoided during phlebotomy because high‑dose vitamin C accelerates iron mobilization beyond transferrin capacity, increasing pro‑oxidant activity and cardiac risk [​15, 16, 14].
• In patients receiving iron chelators, vitamin C intake should be limited to ≤ 200 mg per day [​15].
• Raw shellfish should be avoided due to the heightened risk of Vibrio vulnificus infection in iron‑overloaded individuals [​14].
• Dietary iron restriction is unnecessary; phlebotomy removes approximately 250 mg of iron weekly, far exceeding the 2–4 mg/day reduction achievable by diet [​14].

Management of the Diabetes Component

• Diabetes associated with bronze diabetes is largely irreversible; pancreatic β‑cell damage from iron deposition does not improve with iron removal, and most patients require ongoing insulin therapy [​15, 16].
• A minority of patients may experience a modest reduction in insulin requirements after phlebotomy [​15].

Irreversible vs. Potentially Reversible Manifestations

• Irreversible features that do not respond to phlebotomy: arthropathy, hypogonadism, and established cirrhosis [​15, 16].
• Features that often improve with iron removal: malaise/fatigue, skin hyperpigmentation, abdominal pain, and, in some cases, insulin requirements [​15, 16].

Surveillance for Hepatocellular Carcinoma (HCC)

• All cirrhotic patients should undergo regular HCC surveillance (imaging and α‑fetoprotein), although the optimal screening interval has not been definitively established [​15, 16].
• HCC is exceedingly rare in non‑cirrhotic hemochromatosis, supporting early detection and treatment before cirrhosis develops [​15, 16].
• The risk of HCC persists even after successful iron depletion in patients with established cirrhosis [​15, 16].

Liver Transplantation Considerations

• Decompensated cirrhosis constitutes an indication for evaluation for orthotopic liver transplantation [​14].
• Post‑transplant survival is comparable to other liver disease etiologies when adequate iron removal is achieved pre‑operatively [​14].
• Historically, poor transplant outcomes were linked to peri‑operative cardiac and infectious complications arising from insufficient iron depletion [​14].

Common Pitfalls to Avoid

• Do not postpone phlebotomy while awaiting genetic confirmation if biochemical evidence of iron overload is present; early treatment prevents irreversible organ damage [​15, 16].
• Do not assume that diabetes will improve with iron removal; most patients will continue to need insulin therapy [​15].
• Do not omit liver biopsy when ferritin exceeds 1 000 µg/L, as detection of cirrhosis fundamentally alters prognosis and surveillance strategy [​14].
• Do not allow rapid iron mobilization in patients with known cardiac involvement without close cardiac monitoring [​15, 14].

Prognostic Implications

• The presence of bronze diabetes signifies advanced disease with both cirrhosis and diabetes, which together markedly reduce life expectancy [​15].
• Family screening and early detection before the onset of symptomatic disease are essential to prevent irreversible pancreatic and hepatic injury [​11, 12, 13].

Transferrin Saturation in Iron‑Overload Screening and Management

1. Screening Utility

• Transferrin saturation is a critical first‑line screening marker for iron overload, especially hereditary hemochromatosis, but it must be interpreted together with serum ferritin because it cannot serve as a standalone diagnostic test. [17][18]
• Elevated transferrin saturation is characteristic of hereditary hemochromatosis and reflects disturbed plasma iron homeostasis. 17
• The assay identifies inappropriately low hepcidin levels that drive iron accumulation in hereditary hemochromatosis. 17

2. Prognostic Significance

• All‑cause mortality rises markedly when transferrin saturation exceeds 55 % (hazard ratio 1.60; 95 % CI 1.17–2.21), indicating clinical relevance beyond diagnosis. [19][20]

3. Limitations and Confounding Factors

• Transferrin saturation alone cannot reliably confirm iron overload because serum iron parameters are only indirect surrogates of total body iron stores. [17][18]
• Excessive alcohol intake can raise transferrin saturation independently of genetic hemochromatosis. [17][18]

4. Role of Imaging

• Magnetic resonance imaging (MRI) quantification of hepatic iron is the gold‑standard non‑invasive method for assessing tissue iron overload. [17][18]
• In individuals homozygous for the C282Y HFE mutation who already have high transferrin saturation and hyperferritinemia, MRI is not required for diagnosis but can be used to gauge the severity of overload. [17][18]
• For patients without C282Y homozygosity or who have additional risk factors such as metabolic syndrome or alcohol excess, MRI is essential to guide management decisions. [17][18]

5. Therapeutic Implications

• In patients with metabolic syndrome or chronic liver disease, an elevated transferrin saturation may suggest iron overload, yet current evidence does not conclusively support the benefit of phlebotomy in these groups. [17][18]

MRI R2* Liver Iron Quantification

Preferred Imaging Modality

• MRI with confounder‑corrected R2*‑based relaxometry is the recommended non‑invasive technique for detecting and quantifying hepatic iron concentration, eliminating the need for liver biopsy in most cases. 21

Relationship to Total Body Iron Stores

• Hepatic iron concentration measured by R2* serves as a surrogate marker for total body iron stores because liver iron correlates linearly with overall iron burden. 21

Field Strength and Reproducibility

• MRI R2* can be performed on either 1.5‑Tesla or 3‑Tesla scanners; both field strengths provide accurate and reproducible iron quantification when confounder‑corrected sequences are used. 21